Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2676 - 2700 of 15829 in total

Betrixaban

Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals...
Approved
Investigational
Matched Description: … Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible ... VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable …
Matched Categories: … Blood and Blood Forming Organs …

Oliceridine

Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for...
Approved
Investigational
Matched Iupac: … [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine …
Matched Description: … Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal ... beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and ... G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and …

Peginterferon alfa-2a

Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Investigational
Matched Description: … development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric ... 36% for genotype 1 and 59% for genotypes 2-6 after 48 weeks of treatment. ... the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Efgartigimod alfa

Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction. The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in...
Approved
Investigational
Matched Description: … results in the destruction of these receptors and a reduction in electrical nerve impulses. ... autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and ... acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Roflumilast

Roflumilast is a highly selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is a major cyclic-3',5′-adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme expressed on nearly all immune and pro-inflammatory cells, in addition to structural cells like those of the smooth muscle or epithelium. The resultant increase in intracellular cAMP induced by roflumilast's inhibition of PDE4...
Approved
Matched Description: … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018. ... adenosinemonophosphate (cyclic AMP, cAMP)-metabolizing enzyme [L37564] expressed on nearly all immune and ... The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April …

Bisoctrizole

Bisoctrizole, or methylene bis-benzotriazolyl tetramethylbutylphenol, is a broad-spectrum organic UV filter that is marketed as Tinosorb M . It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays. Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts...
Approved
Matched Iupac: … benzotriazol-2-yl)-6-{[3-(2H-1,2,3-benzotriazol-2-yl)-2-hydroxy-5-(2,4,4-trimethylpentan-2-yl)phenyl]methyl …
Matched Description: … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B ... Bisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a ... UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of …

Pargyline

Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
Approved
Matched Iupac: … benzyl(methyl)(prop-2-yn-1-yl)amine …
Matched Categories: … pargyline and diuretics ... MAO Inhibitors and Diuretics …

Udenafil

Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
Approved
Investigational
Matched Iupac: … 3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl …
Matched Description: … It has been approved in South Korea and will be marketed under the brand name Zydena. …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Ponesimod

Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults.[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than fingolimod. Fingolimod's activity at sphingosine 1-phosphate receptor 3 was suspected to...
Approved
Investigational
Matched Description: … sphingosine 1-phosphate receptor 3 was suspected to be responsible for a portion of it's adverse effects, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Attapulgite

Attapulgite is a magnesium aluminium phyllosilicate which occurs in a type of clay soil common to the Southeastern United States. When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive tract. For that reason, it has often been used in antidiarrheal medications. Until...
Approved
Vet approved
Matched Description: … When used in medicine, it physically binds to acids and toxic substances in the stomach and digestive …
Matched Categories: … Alimentary Tract and Metabolism …

Lebrikizumab

Lebrikizumab is a monoclonal antibody against IL-13 that binds to a different epitope compared tralokinumab.[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 years and older with a body weight...
Approved
Investigational
Matched Description: … adolescent patients 12 years and older with a body weight of at least 40 kg. ... EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and ... This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Suvorexant

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Approved
Investigational
Matched Iupac: … 5-chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole …
Matched Description: … wakefulness and arousal. ... Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing …
Matched Categories: … Hypnotics and Sedatives ... Miscellaneous Anxiolytics Sedatives and Hypnotics …

Pyrvinium

Pyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under investigation.
Approved
Matched Description: … forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and …
Matched Categories: … Antiparasitic Products, Insecticides and Repellents …

Gadopiclenol

Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body. In 2006, the use of GBCAs was associated with the development...
Approved
Matched Description: … hardening of skin and subcutaneous tissues. ... vascularity in the central nervous system and the body. ... It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal …

Phenindione

An indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …

Lactose

A disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Approved
Experimental
Investigational
Matched Description: … A disaccharide of glucose and galactose in human and cow milk. ... It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. …
Matched Categories: … Diet, Food, and Nutrition …

Filgotinib

Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.[A221451,A221456] The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are unable to...
Approved
Investigational
Matched Iupac: … N-(5-{4-[(1,1-dioxo-1lambda6-thiomorpholin-4-yl)methyl]phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide …
Matched Description: … [A189165] JAK2 and JAK3 play important roles in both immune and hematologic functions; therefore, selectivity ... joint symptoms and can limit range of motion in severe cases. ... comorbidities including cardiovascular disease and mental disorders. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tezepelumab

Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling.[A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. Blocking the...
Approved
Investigational
Matched Description: … including eosinophil counts and IgE, FeNO, IL-5, and IL-13 levels. ... endotypes characterized by reduced airflow, chronic inflammation, and airway remodelling. ... Asthma is a heterogeneous chronic obstructive respiratory disease with both "type 2" (T2) and T2-low …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Carbamoylcholine

Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects. Carbamoylcholine was granted FDA approval on 28 September 1972.
Approved
Matched Description: … Carbamoylcholine was initially used as a treatment for migraines,[A226365] induction of diuresis,[A226370] and …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Quinagolide

Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and DB00248 are...
Approved
Investigational
Matched Description: … Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido ... Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the ... It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand …
Matched Categories: … Genito Urinary System and Sex Hormones …

Sarilumab

Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and ... soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL ... [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ozanimod

Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada...
Approved
Investigational
Matched Description: … , physical, and cognitive effects. ... pain, diarrhea, bloody stools, and vomiting. ... It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Technetium Tc-99m pyrophosphate

A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the...
Approved
Matched Description: … used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and …
Matched Categories: … Indicators and Reagents …

BCG vaccine

BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
Approved
Investigational
Matched Description: … investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Chlorpromazine

The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
Approved
Investigational
Vet approved
Matched Description: … Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the …
Displaying drugs 2676 - 2700 of 15829 in total